NCT01894776

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Ottawa Hospital Research Institute · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Healthy volunteers are being recruited for this pharmacokinetics study. The objective is to characterize the pharmacokinetic properties of maraviroc alone and when administered with rifabutin and to assess rifabutin and 25-O-desacetyl-rifabutin pharmacokinetics compared to the literature.

Conditions

• HIV Infection
• HIV-1 Infection
• Mycobacterium Avium Complex (MAC)

Interventions

Type	Name	Description
DRUG	Rifabutin	Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
DRUG	Maraviroc	Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days

Timeline

• Start date: 2013-06-01
• Primary completion: 2013-12-01
• Completion: 2015-02-01
• First posted: 2013-07-10
• Last updated: 2020-03-10
• Results posted: 2020-03-10

Locations

1 site across 1 country: Canada